137 results
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
18 Apr 24
Regulation FD Disclosure
8:30am
debilitating diseases or conditions that affect fewer than five in 10,000 people in the European Union. Orphan designation allows companies certain benefits
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
22 Feb 24
Regulation FD Disclosure
9:30am
in that limitation, the following chart shows you what percentage of the AML population actually benefits from these therapies.
The orange bars
424B3
haqlv
16 Feb 24
Prospectus supplement
5:19pm
8-K
EX-10.1
gpgwib931nc3
5 Jan 24
Departure of Directors or Certain Officers
5:14pm
8-K
EX-10.3
85fmbm407t0
5 Jan 24
Departure of Directors or Certain Officers
5:14pm
8-K
EX-10.2
pfomavn9cfjr pr
5 Jan 24
Departure of Directors or Certain Officers
5:14pm
424B5
65rf99h8
22 Dec 23
Prospectus supplement for primary offering
5:00pm
8-K
EX-10.1
qgig8z eyxmm3e
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-4.1
d8r6 55js9
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-99.1
pr7zbh
20 Nov 23
Regulation FD Disclosure
9:15am
8-K
EX-99.1
75mqxbswkrzaia7r
6 Nov 23
Regulation FD Disclosure
8:35am
8-K
EX-99.1
otnvyp6t9ljemc
21 Sep 23
Regulation FD Disclosure
8:50am
S-8
EX-4.5
snea3 cc93j36
21 Jun 23
Registration of securities for employees
5:16pm